SCHEMBL24535901

SCHEMBL24535901

CC(C)(C)OC(=O)Nc1cc2n(n1)CCCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NR1H2 P55055 2/20 0.42
▸ MAPT P10636 1/20 0.40
▸ ESR2 Q92731 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ RIN1 Q13671 1/20 0.38
▸ PTPN2 P17706 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ PTPN6 P29350 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MMP1 P03956 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30793149 0.98 NR1H2 (0.42) MEN1KMT2ANR1H2MAPTESR2
SCHEMBL29680668 0.91 MEN1 (0.43) MEN1KMT2ANR1H2MAPTESR2
SCHEMBL29080102 0.85 MEN1 (0.42) MEN1KMT2ANPSR1USP30
SCHEMBL16100208 0.83 MAPT (0.40) MEN1KMT2AMAPT
SCHEMBL14929658 0.83 GSK3B (0.38) NPC1RAB9AGSK3BDYRK1A
SCHEMBL12307411 0.81 NR1H2 (0.45) MEN1KMT2ANR1H2MAPTESR2
SCHEMBL30706967 0.81 NR1H2 (0.43) MEN1KMT2ANR1H2MAPTESR2
SCHEMBL16794266 0.81 NR1H2 (0.46) MEN1KMT2ANR1H2MAPTESR2
SCHEMBL25336926 0.80 NR1H2 (0.51) MEN1KMT2ANR1H2MAPTESR2
SCHEMBL24535305 0.80 MEN1 (0.46) MEN1KMT2ANR1H2ESR2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 — — EP disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed
Send feedback